+390677209020 | +39 0267380552 info@direnzo.biz | sedemilano@direnzo.biz | Italian Language

Drug Data Matrix code: what does it mean?

Drug Data Matrix code

Delegated Regulation (EU) 2016/161 of the European Commission (integrating Directive 2001/83/EC of the European Parliament and of the Council) provides for the adoption of a control system via the application of the Data Matrix, a two-dimensional unique identification.

Italy did not adopt this European drug control system immediately, since they already had in place their own tracking mechanism, enjoying a waiver until Legislative Decree no. 10 of 6 February 2025 was issued.

How is drug authenticity verified?

In order to ensure the verification of drug packs, the application of two safety components on the packaging is provided for for medicinal products subject to medical prescription:

  1. Unique identifier (Data Matrix)
  2. Anti tampering device (ATD)

In Italy, a third element will be applied, i.e. a device created on a safety paper (possibly digital).

However, from 9 February 2025 to 9 February 2027 a stabilisation period has been established for all operations to apply, activate, verify and inactivate the Data Matrix, during which it will be still possible to market batches of medicinal products bearing the pharmaceutical antifraud sticker.

Article 13, comma 6, reports as follows:

“In the stabilisation period as per comma 4, the unique identifier and the device as per article 2, comma 2, provided for the human medicines subject to the discipline of the unique identifier as per article 2, section 1, of the delegated regulation (EU) 2016/161, can be replaced by the pharmaceutical sticker as per article 5.2 of legislative decree 30 December 1992 no. 540, also for the purposes of the medicine batch release.”.

Until 9 February 2027, in fact, the antifraud stickers cover all “safety features” provided for by the Legislative Decree of 6 February 2025.

Medicinal products marketed with the stickers can be distributed and supplied to the public in Italy until their expiry date, without being repackaged or relabelled.

Which medicine does the Data Matrix apply to?

The Data Matrix will apply to all medicinal products subject to prescription, except for those specific categories reported in annex I of the delegated Regulation (EU) 2016/161 and to some medicinal products with no obligation, listed in annex II of the Regulation.

What information does the Data Matrix code include?

The Data Matrix code shall essentially include 5 elements, according to the provisions of the Decree of 6 March 2025 of the Ministry of Health:

  1. The product Code (GTIN – Global Trade Item Number)
    1. A 14-digit number identifying the medicines, including the name, pharmaceutical form, strength and type of packaging.
    1. Built according to the GS1 System specifications.
  2. Serial number
    1. Numeric or alpha-numeric (up to 20 characters).
    1. Generated casually by the manufacturer via a randomised algorithm
  3. MA (Marketing Authorisation) code
    1. A 9-digit number assigned by the Italian Medicine Agency (AIFA) for the marketing authorisation in Italy.
  4. Batch Number
    1. alpha-numeric (up to 20 characters) code identifying the production batch of the medicinal product.
  5. Expiry date
    1. Indicated with 6 digits in the format YYMMDD (Year, Month, Day).

Verification of the drugs via the DataMatrix

The DataMatrix code complies with the international technical specifications in order to ensure readability and possible interaction and exchange between the different systems (bodies) using different technologies.

When manufacturers, wholesalers and any subjects authorised or legitimated to supply drugs to the public check the authenticity of a unique identifier, they control it against the unique identifiers present in the archive system.

A unique identifier is authentic when the archive contains a product code and a serial number that is identical to those of the unique identifier subject to verification.

As for the Anti-tampering device (ATD), the device allowing to control if the pack of the medicine was tampered with, drug manufacturers can choose a type among those authorised for the European market.